FibroGen Culture Company

Mr. Thomas B. Neff, also known as Tom, Founded FibroGen, Inc. in 1993 and has been its Chairman and Chief Executive Officer since 1993. Mr. Neff has been General Partner of Three Arch Bay Health Sciences Fund since 1993. He has been General Partner of Pharmaceutical Partners I and Pharmaceutical Partners II since 1993 and 1994. He served as Senior Vice President at Lazard Fr???res & Co., from 1988 to 1992 and PaineWebber Group (now UBS) from 1983 to 1988. He has been a Director of Emed Technologies Corp. since November 1995. Mr. Neff has been a Director at Kolltan Pharmaceuticals, Inc. since March 2009. Mr. Neff has been a Director at FibroGen, Inc since 1993. He serves as a Director of FibroGen China Anemia Holdings, Ltd. He served as a Director of Merge Healthcare North America since November 1995. He serves as Trustee at Claremont McKenna College. Mr. Neff is listed as a named inventor on over twenty-five U.S. and foreign patents and over 100 corresponding U.S. and foreign patent applications related to the FibroGen technology programs. He was a fellow of the Thomas Watson Foundation. Mr. Neff completed his undergraduate studies at Claremont McKenna College., with concentrations in molecular biology and government and graduate studies at the University of Chicago in economics and business. He received a Doctor of Medicine Degree, honoris causa, from Oulu University, Oulu, Finland in 2009.

Mr. Pat Cotroneo has been Chief Financial Officer of FibroGen, Inc since 2008 and serves as its Vice President of Finance. Mr. Cotroneo joined us in 2000 as Controller. Prior to joining us, Mr. Cotroneo was at SyStemix, Inc. where he assumed Controller responsibilities for both SyStemix and Genetic Therapy, Inc. (Novartis subsidiaries) from 1993 to 2000. He was employed by Deloitte & Touche from 1987 to 1993 in various positions. Mr. Cotroneo received a B.S. with honors from the University of San Francisco.

Dr. K. Peony Yu, M.D. has been the Chief Medical Officer of FibroGen, Inc. since April 1, 2016 and served as its Vice President of Clinical Development since December 2008 until April 01, 2016. Dr. Yu has expertise in design and execution of all phases of clinical development programs, including clinical and regulatory strategy, interactions with regulatory authorities in the US and EU, as well as experience with successful leadership of clinical teams. Dr. Yu served as Vice President of Clinical Research at Anesiva, Inc. since June 2006, where she was responsible for management of clinical research, statistics/data management, clinical operations and medical affairs/medical information for all clinical programs, including the late-stage clinical development and approval of Zingo(TM). Dr. Yu worked at ALZA Corporation as a Director of Clinical Development from August 2004 to June 2006. There, she served as IONSYS(TM) Global Clinical Team Leader and contributed to the recent FDA approval and marketing authorization in the European Union of IONSYS(TM) for the management of acute post-operative pain. She also contributed to the in-licensing of pain products and new product concepts as well as assisted in the submission of a new drug application (NDA) for a urology product. Dr. Yu served as a Director of Clinical Development at Pain Therapeutics, Inc. from October 2001 to July 2004, responsible for the clinical development program for Remoxy(TM) and OxyTrex(TM), both for the management of moderate to severe chronic pain and an Assistant Director of Clinical Affairs at Elan Pharmaceuticals from July 2000 to September 2001, where she contributed to the development of PRIALT(R). She had nearly a decade of clinical experience at the Palo Alto Medical Foundation, where Dr. Yu founded physical medicine and rehabilitation department and co-founded its pain management service. Dr. Yu is board certified by both the American Board of Physical Medicine and Rehabilitation and the American Board of Pain Medicine. Dr. Yu received her Medical Degree from the University of California-Davis and completed a Residency at Stanford University School of Medicine.

Dr. Barry A. Berkowitz, Ph.D. has been the President and Chief Executive Officer of Cetek Corp., since December 2005. Dr. Berkowitz serves as Corporate Vice President at Albany Molecular Research Inc. Dr. Berkowitz served as the President and Chief Executive Officer of Scion Pharmaceuticals Inc. Dr. Berkowitz is a Founder and served as the Chief Executive Officer of New Chemical Entities, Inc.; ChemGenics Pharmaceuticals, Inc. and Magainin Pharmaceuticals, Inc. (now Genaera Corporation). He also held research executive positions at SmithKline & French (now Glaxo SmithKline) and research positions at the Roche Institute of Molecular Biology. Dr. Berkowitz has had an extensive and successful career in the biotechnology and pharmaceutical industries as an executive in drug discovery and development and as an entrepreneur. Dr. Berkowitz's industry career spans 30 years. He Founded Fibrogen Inc. in 1995. He serves as a Director at Cetek Corporation and serves as Member of Industrial Advisory Board at Sitka Limited. Dr. Berkowitz is an Author on more than 100 scientific publications and is a Co-inventor on a number of U.S. patents. Dr. Berkowitz earned his Bachelor of Science degree at Northeastern University in Pharmacy and received his Ph.D. in pharmacology from the University of California, San Francisco.

Mr. James A. Schoeneck, also known as Jim, serves as a Strategic Advisor to Kreido Laboratories. Mr. Schoeneck served as the Chief Executive Officer and President of DepoMed, Inc. from April 18, 2014 to March 28, 2017. He served as the Chief Executive Officer of BrainCells Inc. since October 2005. Mr. Schoeneck served as Chief Executive Officer of ActivX Biosciences Inc., from November 2003 to December 2004. Mr. Schoeneck served as President and Chief Executive Officer of Prometheus Laboratories Inc. from 2000 to 2003 and previously served as its President and Chief Operating Officer. At Prometheus, he led their business strategy, research and operations during a period of exceptional growth and transformation. Prior thereto, Mr. Schoeneck served as Vice President and General Manager, Immunology Business Unit at Centocor, Inc. He built and successfully launched Remicade, a leading biologic for rheumatoid arthritis and Crohn's disease that now exceeds $3 billion in annual sales. He served as Vice President of Marketing and Commercial Development at Johnson & Johnson subsidiary, Centocor, Inc. He negotiated and led Centocor's strategic partnership with Schering-Plough for Remicade rights outside the U.S and worked with Lilly and GSK on other monoclonal antibody-based partnerships. He spent 13 years at Rhone-Poulenc Rorer, Inc. where he held multiple sales and marketing positions, including Director of Healthcare Services, Director of Marketing and various other positions. He has been a Director of FibroGen, Inc. since April 2010. He has been a Director of AnaptysBio, Inc. since November 19, 2015. He served as a Director of BrainCells, Inc. since October 2005. He served as a Director of ActivX Biosciences, Inc. He served as a Director at DepoMed, Inc. from December 2007 to March 28, 2017. He served for 2 years as Chairman of the Board at the Asthma and Allergy Foundation of America. Mr. Schoeneck served on the Board of Directors of BIOCOM and AAFA. Mr. Schoeneck holds a BS Degree in Education from Jacksonville State University.

Dr. George R. Martin, Ph.D, served as a Senior Vice President of Scientific Affairs of FibroGen, Inc. Dr. Martin is a Scientist Emeritus at National Institute of Health. Dr. Martin joined FibroGen in 1994 as Vice President for Scientific Affairs. Dr. Martin has a distinguished career included positions at several entities within the National Institutes of Health; the Weizmann Institute of Science, the Max-Planck Institute fur Biochemie; Scientific Director of National Institute on Aging and Director of Gerontology Research Center. At National Institutes, he was responsible for managing the NIA Gerontology Research Center in Baltimore, Maryland, and directing the Intramural Research Program, a multi-disciplinary program with numerous independent laboratories and branches. He also served as Chief of the Laboratory of Developmental Biology of the National Institute of Dental and Craniofacial Research (NIDCR), NIH. Dr. Martin serves as Chairman of Scientific Advisory Board of FibroGen, Inc. He serves as a Member of Scientific Advisory Board of GenePharm, Inc., Greystone Pharmaceuticals, Inc. and SanBio Inc. He serves as a Member of the Editorial Board of Cell Biology and Toxicology. He also served as an Adjunct Professor of Stanford University. Dr. Martin received his Ph.D. in Pharmacology and Biochemistry from the University of Rochester and his B.A. in Chemistry from Colgate University. Dr. Martin has trained numerous scientific investigators, received a number of honors and awards, and published over 300 articles in such areas as collagen, wound healing, developmental biology, aging, cell biology, and molecular biology.

Ms. Leanne C. Price has been Chief Intellectual Property Counsel at FibroGen, Inc. since April 21, 2016. Ms. Price served as Vice President of Intellectual Property and Corporate Strategy at Fibrogen Inc. Ms. Price served as Vice President of Intellectual Property at Fibrogen Inc. Ms. Price, Chief Intellectual Property Counsel, joined FibroGen in 1999. She has approximately 25 years of in-house and law firm experience with an emphasis on patent portfolio development and defense and intellectual property strategy in the biotechnology and pharmaceutical industries. Ms. Price was previously Senior Patent Attorney at Incyte Pharmaceuticals, where she was responsible for global management of Incyte's core technology portfolio. Prior, Ms. Price was an associate at the Silicon Valley law firm of Skjerven Morrill MacPherson Franklin & Friel LLP, focused on the areas of patent prosecution and defense, licensing and intellectual property counseling. Ms. Price received a B.S. in Molecular Biology and a B.A. in History Honors with high distinction from Revelle College at the University of California, San Diego. She received her J.D. from Boalt Hall, School of Law (University of California, Berkeley). Ms. Price is a member of the State Bar of California and is registered to practice before the United States Patent and Trademark Office.

Ewa Carrier serves as the Executive Director of FibroGen, Inc.. Ewa started at FibroGen, Inc. in June of 2016. Ewa is currently based in the San Francisco Bay Area.

Ted Tucker serves as the Vice President, Human Resources of FibroGen, Inc.. Ted started at FibroGen, Inc. in September of 1997. Ted currently resides in San Francisco Bay Area.